ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Research description

ADC Therapeutics has a deep understanding of antibody drug conjugate technology and the oncology treatment landscape. The company is dedicated to efficiently progressing its potential best-in-class PBD-armed ADCs to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

These PBD-based ADCs cause antigen-targeted antibodies to bind to specific tumor cell surface antigens. The drug conjugate is internalized and the potent PDB dimer is released inside the cell. There it creates a covalent cross-link between the strands of the DNA double helix. Because these cross links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division.